All Stories

  1. Development of an Enzyme-Mediated, Site-Specific Method to Conjugate Toll-Like Receptor 2 Agonists onto Protein Antigens: Towards a Broadly Protective, Four Component, Group A Streptococcal Self-Adjuvanting Lipoprotein-Fusion Combination Vaccine

    Article • ACS Infectious Diseases, May 2020, American Chemical Society (ACS)

    Zhenghui Xu

  2. Semisynthetic, self-adjuvanting vaccine development: Efficient, site-specific sortase A-mediated conjugation of Toll-like receptor 2 ligand FSL-1 to recombinant protein antigens under native conditions and application to a model group A streptococcal v...

    Article • Journal of Controlled Release, January 2020, Elsevier

    Dr Peter Michael Moyle, Zhenghui Xu

  3. A Self‐Adjuvanting Vaccine Platform: Optimization of Site‐Specific Sortase A Mediated Conjugation of Toll‐Like Receptor 2 Ligands onto the Carboxyl or Amino terminus of Recombinant Protein Antigens

    Article • ChemPlusChem, January 2020, Wiley

    Zhenghui Xu

  4. Improving vaccines by attaching immunostimulatory Toll-like receptor ligands onto protein antigens

    Article • Bioconjugate Chemistry, September 2017, American Chemical Society (ACS)

    Dr Peter Michael Moyle, Zhenghui Xu

  5. Site-specific bioconjugation of toll-like receptor ligands onto folded recombinant protein antigens using enzyme-mediated ligation

    Article • University of Queensland Library

    Zhenghui Xu